FOLH1 and prostate carcinoma: With regard to metastatic castration-resistant prostate cancer, though there are no ADCs approved for prostate cancer, there are some ADCs targeting different antigens in clinical studies, such as PSMA, TROP-2, STEAP1, TF and DLL-3 (Sardinha et al., 2023).